Credit Suisse: Upgraded Clover Bio-B (02197) rating to “outperform the market” and raised the target price to HK$3.4
Hong Kong stocks change | Shamrock-B (02197) falls by nearly 10% Credit Suisse says reduced demand for Gavi vaccine downgraded the company's rating to "neutral"
IPO News: Clover Biopharmaceuticals Co., Ltd. - B (2197.HK)
No Data
No Data